JPS58192821A - 脳神経細胞の酸素欠乏性疾患の治療剤 - Google Patents

脳神経細胞の酸素欠乏性疾患の治療剤

Info

Publication number
JPS58192821A
JPS58192821A JP57074175A JP7417582A JPS58192821A JP S58192821 A JPS58192821 A JP S58192821A JP 57074175 A JP57074175 A JP 57074175A JP 7417582 A JP7417582 A JP 7417582A JP S58192821 A JPS58192821 A JP S58192821A
Authority
JP
Japan
Prior art keywords
group
lower alkyl
nerve cells
active ingredient
anoxia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57074175A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0213644B2 (cg-RX-API-DMAC10.html
Inventor
Yoshinobu Masuda
増田　義信
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Sumitomo Pharma Co Ltd
Original Assignee
Dainippon Pharmaceutical Co Ltd
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Pharmaceutical Co Ltd, Ono Pharmaceutical Co Ltd filed Critical Dainippon Pharmaceutical Co Ltd
Priority to JP57074175A priority Critical patent/JPS58192821A/ja
Priority to DE19833315356 priority patent/DE3315356A1/de
Priority to BE0/210672A priority patent/BE896621A/fr
Priority to US06/490,223 priority patent/US4499085A/en
Publication of JPS58192821A publication Critical patent/JPS58192821A/ja
Publication of JPH0213644B2 publication Critical patent/JPH0213644B2/ja
Granted legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
JP57074175A 1982-04-30 1982-04-30 脳神経細胞の酸素欠乏性疾患の治療剤 Granted JPS58192821A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP57074175A JPS58192821A (ja) 1982-04-30 1982-04-30 脳神経細胞の酸素欠乏性疾患の治療剤
DE19833315356 DE3315356A1 (de) 1982-04-30 1983-04-28 Verwendung von prostaglandinanalogen
BE0/210672A BE896621A (fr) 1982-04-30 1983-04-29 Nouvelle utilisation therapeutique d'analogues de prostaglandines
US06/490,223 US4499085A (en) 1982-04-30 1983-04-29 Method of anoxia treatment using prostaglandin analogues

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP57074175A JPS58192821A (ja) 1982-04-30 1982-04-30 脳神経細胞の酸素欠乏性疾患の治療剤

Publications (2)

Publication Number Publication Date
JPS58192821A true JPS58192821A (ja) 1983-11-10
JPH0213644B2 JPH0213644B2 (cg-RX-API-DMAC10.html) 1990-04-04

Family

ID=13539557

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57074175A Granted JPS58192821A (ja) 1982-04-30 1982-04-30 脳神経細胞の酸素欠乏性疾患の治療剤

Country Status (2)

Country Link
JP (1) JPS58192821A (cg-RX-API-DMAC10.html)
BE (1) BE896621A (cg-RX-API-DMAC10.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130519A (ja) * 1984-07-23 1986-02-12 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患治療剤
AT395943B (de) * 1987-12-22 1993-04-26 Glaxo Group Ltd Pharmazeutische waessrige formulierungen, die ein piperidinylcyclopentylheptensaeure-derivat enthalten
JPH07107020B2 (ja) * 1986-03-07 1995-11-15 シエ−リング アクチエンゲゼルシヤフト カルバサイクリン誘導体のシクロデキストリンクラスレート
WO1998041209A1 (fr) * 1997-03-14 1998-09-24 Toray Industries, Inc. Agents protecteurs de la cellule nerveuse
US7071359B1 (en) 1999-08-05 2006-07-04 Teijin Limited Neuropathy improvers containing nitrogenous compounds as the active ingredient

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6130519A (ja) * 1984-07-23 1986-02-12 Dainippon Pharmaceut Co Ltd 脳神経細胞の酸素欠乏性疾患治療剤
JPH07107020B2 (ja) * 1986-03-07 1995-11-15 シエ−リング アクチエンゲゼルシヤフト カルバサイクリン誘導体のシクロデキストリンクラスレート
AT395943B (de) * 1987-12-22 1993-04-26 Glaxo Group Ltd Pharmazeutische waessrige formulierungen, die ein piperidinylcyclopentylheptensaeure-derivat enthalten
WO1998041209A1 (fr) * 1997-03-14 1998-09-24 Toray Industries, Inc. Agents protecteurs de la cellule nerveuse
US7071359B1 (en) 1999-08-05 2006-07-04 Teijin Limited Neuropathy improvers containing nitrogenous compounds as the active ingredient

Also Published As

Publication number Publication date
BE896621A (fr) 1983-11-03
JPH0213644B2 (cg-RX-API-DMAC10.html) 1990-04-04

Similar Documents

Publication Publication Date Title
JPS62215527A (ja) アルツハイマー病治療薬
DE69934305T2 (de) Verwendung von dexmedetomidine zur sedierung auf der intensivstation
JP3852621B2 (ja) 血管内皮細胞機能改善剤
JP2010510973A (ja) 心筋組織の壊死を処置するためのホスホエノールピルビン酸誘導体の使用
JP5680412B2 (ja) レオヌリンの使用およびその組成物
KR20010032009A (ko) 수면성 무호흡의 치료에 미타자핀을 사용하는 방법
JP2720348B2 (ja) 脳細胞機能障害改善剤
JP2001515479A (ja) 偏頭痛治療におけるレボブピバカインまたはロピバカインの使用
JPS58192821A (ja) 脳神経細胞の酸素欠乏性疾患の治療剤
JPH0129168B2 (cg-RX-API-DMAC10.html)
JP2009501737A (ja) レイノー現象の処置のための可溶性グアニル酸シクラーゼ活性化剤の使用
Wilkerson et al. Influence of nonsteroidal anti-inflammatory drugs on ouabain toxicity
JPS6089417A (ja) エピニンあるいはその製薬的に許容しうる塩を含む医薬組成物ならびに用途
CH644016A5 (de) Arzneimittel zur behandlung hypertoner funktionszustaende der harnblase.
JPH06263636A (ja) 脳または高次神経疾患治療剤
US20040180895A1 (en) Use of a pyridazinone derivative
Kross et al. No dantrolene protection in a dog model of complete cerebral ischaemia
Chu Prevention of alcohol withdrawal seizures with phenytoin in rats
JP2010248263A (ja) 塩酸ランジオロールを含有する頻脈性不整脈の治療剤
JPS63152317A (ja) 脳虚血性病変を伴う疾患治療剤
JPS61236725A (ja) 脳浮腫抑制剤
JPH0761939B2 (ja) 脳への酸素供給を増進させる薬剤組成物および該薬剤組成物の製造方法
WO2025152110A1 (zh) 用于阿尔兹海默症治疗的联合用药及其药物组合物
JP2949366B2 (ja) 心臓疾患の予防または治療剤
Kundig Studies in primates on the manifestations and treatment of fenfluramine intoxication